SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 71.00 |
| Enterprise Value ($M) | 35.67 |
| Book Value ($M) | 50.10 |
| Book Value / Share | 13.96 |
| Price / Book | 1.42 |
| NCAV ($M) | 41.49 |
| NCAV / Share | 11.56 |
| Price / NCAV | 1.71 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.30 |
| Return on Assets (ROA) | -0.90 |
| Return on Equity (ROE) | -1.40 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.81 |
| Current Ratio | 3.81 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 79.82 |
| Assets | 88.43 |
| Liabilities | 38.33 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Alyeska Investment Group, L.P. | 4.80 | -97.96 | |
| 13G/A | EcoR1 Capital, LLC | 9.99 | -95.10 | |
| 13G/A | Vivo Capital Fund VIII, L.P. | 4.00 | ||
| 13G/A | Hillhouse Capital Advisors, Ltd. | 4.00 | -97.91 | |
| 13G/A | Armistice Capital, Llc | 9.99 | -95.57 | |
| 13G | Adage Capital Management, L.P. | 7.12 | ||
| 13G | Ics Opportunities Ii Llc | 4.10 | ||
| 13G/A | Tang Capital Partners Lp | 3.00 | -22.25 | |
| 13G/A | Baker Bros. Advisors Lp | 4.99 | 76.46 | |
| 13D/A | Versant Venture Capital VI, L.P. | 1.90 | 0.00 | |
| 13G/A | Roche Finance Ltd | 15.35 | 256.56 | |
| 13D | Blatt Lawrence | 5.30 | 45.19 | |
| 13G | Deep Track Capital, LP | 9.99 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 134,923 | 412,931 | 32.67 | |
| 217,643 | 611,231 | 35.61 | |
| 145,329 | 458,161 | 31.72 | |
| 458,581 | 1,481,558 | 30.95 | |
| 120,721 | 364,998 | 33.07 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AKBA – Akebia Therapeutics, Inc. | ALBT – Avalon GloboCare Corp. |
| ALDX – Aldeyra Therapeutics, Inc. | ALRN – Aileron Therapeutics, Inc. |
| ALTS – JanOne Inc. |
Financial data and stock pages provided by
Fintel.io